9/12 5:30 pm - 8:30 pm
HBA presents 'Putting Academia-Industry Research Partnerships to Work.' Novartis, 1 Health Plaza, East Hanover, NJ more
9/24 4:00 pm - 6:00 pm
CURE presents healthcare investment banker Anthony Gibney of Leerink Swann. Yale Anlyan Center, 300 Cedar Street, New Haven more
10/1 4:00 pm - 6:00 pm
CURE/Yale BioHaven presents Trevi Therapeutics. Anlyan Center, 300 Cedar Street, New Haven. Watch for details.
10/8-9 12th annual BIO Investor Forum. The Palace Hotel, San Francisco more
10/15 6:00 pm - 9:30 pm
HBA presents Women's Healthcare Innovation and Leadership Showcase. Sanofi Campus, 55 Corporate Drive Auditorium, Bridgewater, NJ more
11/7 10:00 am - 3:00 pm
CT Innovation Summit. Mentor meetings, awards ceremony, and more. Co-sponsored by CURE. Oakdale Theater, Wallingford more
11/11-13 The BIO Convention in China. National Convention Center, Beijing more
12/3 5:45 pm - 7:30 pm
CURE Holiday Party. 'The best networking in town.' Café George, 300 George Street, New Haven. Save the Date!

Cost-saving discounts for CURE members!
CURE members can now receive discounts on various products and services, such as lab supplies, shipping services, and gases more


JS Genetics
2 Church Street South
Suite B-05
New HAven, CT 06519

Phone: 203-570-8275
Fax: 888-852-6699
Website: http://www.jsgenetics.com

Contact(s)
Alidad Mireskandari, President & CEO - a.mireskandari@jsgenetics.com

General Information
JS Genetics, a private company spun out of Yale University Medical School laboratories of two distinguished pediatricians, develops and markets DNA diagnostic tests for underserved medical conditions in newborns and adolescents. The Company’s principle strategy is to internally develop and market accurate, convenient and cost effective PCR based DNA screening tests for adolescents focused in key areas of developmental disorders using buccal swabs as opposed to blood. The use of cheek swabs makes our tests easy to administer while the PCR-based approach used to develop them is low-cost and scalable for high throughput. Our first product, a test for the detection of Turner Syndrome will be marketed in 1H 2010.

Research Activities
Our R&D; is focused in three key areas of developmental disorders caused by chromosomal abnormalities:

  • Physical Developmental Disorders: Turner syndrome, Klinefelter syndrome & Down’s Syndrome
  • Cognitive Developmental Disorders: Dyslexia
  • Behavioral Developmental Disorders: Fragile X
The Turner syndrome test is will be commercially available in 1H 2009. Our second product, a test for Klinefelter syndrome is on track for a 4Q 2010 commercial launch. All of our R&D; has been funded though NIH sponsored SBIR grants.

We also are conducting proof-of-concept studies on a therapeutic drug for the treatment of Periventricular White Matter Injury (PWMI) in premature infants which we plan to out-license this product to a drug development partner after conducting our proof of concept studies.

Other Information
Ownership: Private
CT Employees: 3
World Employees: 4

Back